AAM Slams Medicare Delays For First Generics
US Association Urges Federal And State Policymakers To Act
The AAM has cited multiple reasons for the failure of Medicare Part D to get new generics to its patients, forcing up their costs. The association has offered a list of suggestions to “ensure that first generics are covered at launch, with lower cost-sharing.”
You may also be interested in...ï»¿
An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.
Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.